LianBio Starts China Trials of Gastric Cancer Therapy
publication date: Aug 25, 2021
LianBio, a Shanghai-Princeton in-licensing company, has started a China Phase IIa trial of infigratinib, an FGFR2 inhibitor. The trial will enroll patients who have gastric cancer or gastroesophageal junction adenocarcinoma with FGFR2 gene amplification. One year ago, LianBio acquired China rights to the candidate from BridgeBio as part of a two-drug, $531 million agreement. Infigratinib, which is approved in the US to treat cholangiocarcinoma with a FGFR2 fusion, is the first LianBio asset to start clinical trials. More details....
Stock Symbol: (NSDQ: BBIO)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.